Aadi Bioscience, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.6M
Doctors Paid
583
Transactions
2,682
2024 Total
$21.2M
Payment Breakdown by Category
Research$38.8M (97.9%)
Consulting$342,321 (0.9%)
Food & Beverage$51,210 (0.1%)
Travel$29,303 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.8M | 1,512 | 97.9% |
| Honoraria | $366,675 | 141 | 0.9% |
| Consulting Fee | $342,321 | 82 | 0.9% |
| Food and Beverage | $51,210 | 827 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,305 | 19 | 0.1% |
| Travel and Lodging | $29,303 | 66 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 4 | 0.0% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research
$38.8M
1,508 transactions
General
$850,838
1,170 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | $14.9M | 0 | 51 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | $7.1M | 0 | 31 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | $6.3M | 0 | 327 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | $3.7M | 2 | 467 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | $2.7M | 1 | 271 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $2.5M | 0 | 4 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $494,611 | 0 | 315 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | $475,934 | 0 | 23 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | $294,203 | 0 | 2 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | $218,068 | 0 | 8 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | $58,869 | 0 | 5 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $38,440 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Jason Hornick, Md Phd, MD PHD | Anatomic Pathology | Boston, MA | $2,236 | $0 |
| Andrew Folpe, M.d, M.D | Anatomic Pathology & Clinical Pathology | Rochester, MN | $2,200 | $0 |
| Mr. John Charlson, M.d, M.D | Hematology & Oncology | Milwaukee, WI | $2,160 | $0 |
| Vaia Florou, Md, MD | Internal Medicine | Salt Lake City, UT | $2,055 | $0 |
| Dr. Daniel Lefler, Md, MD | Internal Medicine | Philadelphia, PA | $2,055 | $0 |
| Nam Bui, Md, MD | Medical Oncology | Stanford, CA | $2,055 | $0 |
| Jorge Nieva, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $2,000 | $0 |
| Dr. Fernanda Musa, M.d, M.D | Student in an Organized Health Care Education/Training Program | Seattle, WA | $1,914 | $0 |
| Scott Okuno, M.d, M.D | Medical Oncology | Rochester, MN | $1,823 | $0 |
| Erin Schenk, Md, MD | Hematology & Oncology | Aurora, CO | $1,820 | $0 |
| Dr. Anthony Conley, M.d, M.D | Medical Oncology | Houston, TX | $1,762 | $0 |
| Brian Schulte | Hematology & Oncology | San Francisco, CA | $1,762 | $0 |
| Dr. Neeta Somaiah, M.d, M.D | Internal Medicine | Houston, TX | $1,605 | $0 |
| Michael Wagner | Medical Oncology | Boston, MA | $1,550 | $0 |
| Dr. Jason Sicklick, M.d, M.D | Surgery | La Jolla, CA | $1,550 | $0 |
| Evan Yu | Medical Oncology | Seattle, WA | $1,500 | $0 |
| Dr. Terence Friedlander, Ms, MS | Hematology & Oncology | San Francisco, CA | $1,500 | $0 |
| Dr. Thai Ho, M.d./Ph.d, M.D./PH.D | Internal Medicine | Scottsdale, AZ | $1,500 | $0 |
| Dr. Oladapo Yeku, M.d, Phd, M.D, PHD | Medical Oncology | Boston, MA | $1,500 | $0 |
| Dr. Emmanuel Antonarakis, M.d, M.D | Medical Oncology | Minneapolis, MN | $1,500 | $0 |
| Abhishek Tripathi, M.d, M.D | Internal Medicine | Duarte, CA | $1,500 | $0 |
| Ulka Vaishampayan, Md, MD | Medical Oncology | Ann Arbor, MI | $1,500 | $0 |
| Dr. Daniel Petrylak, M.d, M.D | Hematology & Oncology | New Haven, CT | $1,500 | $0 |
| Dr. Elisabeth Heath, Md, MD | Internal Medicine | Rochester, MN | $1,500 | $0 |
| Donald Lamm, M.d, M.D | Urology | Phoenix, AZ | $1,500 | $0 |
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. has made $39.6M in payments to 583 healthcare providers, recorded across 2,682 transactions in the CMS Open Payments database. In 2024, the company paid $21.2M. The top product by payment volume is FYARRO ($23.1M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Medical Oncology ($341,757 to 68 doctors).
Payment categories include: Food & Beverage ($51,210), Consulting ($342,321), Research ($38.8M), Travel & Lodging ($29,303).
Aadi Bioscience, Inc. is associated with 3 products in the CMS Open Payments database.